CJC-1295 With Ipamorelin Peptide: What the Research Shows

CJC-1295 with ipamorelin is a two-peptide stack studied for its effect on growth hormone (GH) release. CJC-1295 is a growth hormone-releasing hormone (GHRH) analog, and ipamorelin is a selective ghrelin receptor agonist. Neither peptide is FDA-approved for human use in the United States, and both are sold almost exclusively as research chemicals.

The question most people start with — what is cjc-1295 ipamorelin — has a short answer: the pair activates two different receptors on the pituitary gland, which researchers believe produces a larger and more sustained GH pulse than either peptide alone.

What Each Peptide Does

CJC-1295 mimics the body's own GHRH signal. It binds GHRH receptors in the pituitary and tells the gland to release growth hormone, extending the duration of that signal when the DAC version is used.

Ipamorelin mimics ghrelin, the hunger hormone that also triggers GH release. Unlike older ghrelin mimetics such as GHRP-6, ipamorelin was designed to be selective, and early research found it raised GH with less spillover into cortisol and prolactin.

• CJC-1295: raises the amplitude and duration of GH pulses.
• Ipamorelin: triggers a sharp, short GH pulse with minimal appetite effect.
• Combined: studied for a stronger, more natural-looking GH rhythm.

How the Two Peptides Work Together

Growth hormone output depends on the balance between GHRH and ghrelin signaling. Supplying both signals at once is the entire rationale behind the stack. Published work on GHRH analogs and ghrelin mimetics shows a synergistic effect on GH release when the two are combined.

Feature	CJC-1295	Ipamorelin
Peptide class	GHRH analog	Ghrelin receptor agonist
Target receptor	GHRH-R	GHS-R1a
Half-life	About 6-8 days with DAC; about 30 minutes without	About 2 hours
Main effect	Longer, stronger GH pulses	Short, sharp GH pulse
Appetite impact	Low	Mild

CJC-1295 With DAC or Without: What Changes

The DAC (Drug Affinity Complex) version of CJC-1295 carries a maleimide group that binds to albumin in the bloodstream. That bond stretches the half-life from roughly half an hour to about a week. The non-DAC form, often labeled mod GRF 1-29, behaves like a short-acting peptide.

Deciding between cjc-1295 ipamorelin with dac or without usually comes down to injection frequency. The DAC version is studied with once- or twice-weekly shots, while the non-DAC version is studied with multiple daily shots.

Most research protocols pair ipamorelin with the non-DAC form so that the two half-lives line up and both peptides peak at the same time.

Dosage Ranges Reported in Research

There is no standardized human dose for this stack. The figures below come from published research protocols and user-reported logs, not from FDA labeling or clinical guidance.

Compound	Reported research range	Typical frequency
CJC-1295 with DAC	1-2 mg per week	1-2 injections per week
CJC-1295 without DAC	100 mcg per dose	2-3 times daily
Ipamorelin	100-200 mcg per dose	2-3 times daily
Combined stack	100 mcg CJC-1295 plus 100-200 mcg ipamorelin	2-3 times daily

Conversations about cjc-1295 dac with ipamorelin dosage tend to focus on weekly totals rather than single injections, because the DAC form stays active for days.

Best Time to Take CJC-1295 Ipamorelin

Timing matters because natural GH release peaks during deep sleep and is blunted by food, especially fats and carbohydrates.

• Evening dosing 30-60 minutes before bed is the most commonly reported approach.
• Injections are usually taken on an empty stomach, at least two hours after eating.
• When dosing more than once a day, extra doses are placed on waking or after training.

Interest in the best time to take cjc 1295 ipamorelin reflects a simple idea: an injection that lines up with the body's overnight GH surge may add to that surge rather than compete with it.

How It Compares to Tesamorelin and Other Peptides

Tesamorelin is the only GHRH analog with FDA approval, and it is cleared for reducing visceral fat in adults with HIV-associated lipodystrophy. CJC-1295 has no comparable approval. Comparisons of cjc-1295 ipamorelin vs tesamorelin come down to approval status, half-life, and the fact that tesamorelin is studied as a single agent.

Other peptides often mentioned in the same conversation include AOD 9604, which targets fat metabolism rather than GH release, and IGF-1 LR3, which acts downstream on the receptor GH itself stimulates.

Option	Mechanism	FDA status	Common research focus
CJC-1295 plus ipamorelin	GHRH and ghrelin receptor	Not approved	GH pulse stimulation
Tesamorelin	GHRH analog	Approved for HIV lipodystrophy	Visceral fat reduction
AOD 9604	HGH fragment 176-191	Not approved	Fat metabolism
IGF-1 LR3	IGF-1 analog	Not approved	Downstream growth signaling

Safety and Legal Status

CJC-1295 is not FDA-approved for human use in the United States. Ipamorelin is not FDA-approved for human use either. Products sold online carry 'for research use only' labels, and their purity, identity, and sterility are not verified by any regulator.

Commonly reported side effects include injection-site irritation, water retention, tingling or numbness in the hands, headaches, and increased appetite. Sustained elevation of GH and IGF-1 over long periods is a theoretical concern, because both hormones can drive tissue growth.

Anyone considering these peptides should discuss it with a licensed healthcare professional first. Self-dosing with unregulated research chemicals carries risks that no online protocol can offset.

COMMON QUESTIONS

Frequently Asked Questions

Is CJC-1295 with ipamorelin legal in the United States?

Neither peptide is FDA-approved for human use. They can be sold as research chemicals labeled 'not for human consumption,' but personal use is not sanctioned, and the FDA has issued warnings about unapproved peptides marketed online. Buyers should assume no regulatory oversight of purity or sterility.

How often do you inject CJC-1295 with ipamorelin?

It depends on which form of CJC-1295 is used. Research protocols with the non-DAC version typically inject the stack two to three times per day, usually before bed and around training. The DAC version has a half-life of roughly a week, so it is studied with one or two injections per week.

What results can you expect from CJC-1295 with ipamorelin?

Studies of each peptide individually show measurable increases in growth hormone and IGF-1 levels, and the stack is assumed to amplify that response. There are no large controlled trials of the combination in healthy adults. No evidence shows the stack improves body composition, recovery, or long-term health on its own.